Time flies! The DCRT was officially founded 2 years ago by Professor Annemieke Aartsma-Rus (LUMC), Professor Willeke van Roon-Mom (LUMC), and Professor Rob Collins (RUMC), later joined by Professor Ype Elgersma (EMC). Inspired by the N=1 anti-sense oligonucleotide therapy Milasen against Batten's disease, they set out to start a center of their own, providing customized RNA therapies to patients in the Netherlands. Their extensive backgrounds and expertise in antisense oligonucleotide therapeutics are the basis for developing therapies for patients with an ultra-rare disease. In the past 2 years, the DCRT family has steadily grown, with many people dedicated to delivering bespoke drugs to patients. The DCRT strives for an antisense oligonucleotide therapy for Dutch patients but aims to share all the knowledge gained along the way. Did you know there is also an international N=1 Collaborative (n1collaborative.org) of clinician-scientists, researchers, patients, and companies focused on individualized medicine?

published on Feb 28, 2022